These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 15378027)

  • 1. CpG island promoter hypermethylation of the Ras-effector gene NORE1A occurs in the context of a wild-type K-ras in lung cancer.
    Irimia M; Fraga MF; Sanchez-Cespedes M; Esteller M
    Oncogene; 2004 Nov; 23(53):8695-9. PubMed ID: 15378027
    [TBL] [Abstract][Full Text] [Related]  

  • 2. NORE1A, a homologue of RASSF1A tumour suppressor gene is inactivated in human cancers.
    Hesson L; Dallol A; Minna JD; Maher ER; Latif F
    Oncogene; 2003 Feb; 22(6):947-54. PubMed ID: 12584574
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Frequent promoter hypermethylation of RASSF1A and CASP8 in neuroblastoma.
    Lázcoz P; Muñoz J; Nistal M; Pestaña A; Encío I; Castresana JS
    BMC Cancer; 2006 Oct; 6():254. PubMed ID: 17064406
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epigenetic inactivation of the NORE1 gene correlates with malignant progression of colorectal tumors.
    Lee CK; Lee JH; Lee MG; Jeong SI; Ha TK; Kang MJ; Ryu BK; Hwangbo Y; Shim JJ; Jang JY; Lee KY; Kim HJ; Chi SG
    BMC Cancer; 2010 Oct; 10():577. PubMed ID: 20969767
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Aberrant methylation of RASSF4/AD037 in nasopharyngeal carcinoma.
    Chow LS; Lo KW; Kwong J; Wong AY; Huang DP
    Oncol Rep; 2004 Oct; 12(4):781-7. PubMed ID: 15375500
    [TBL] [Abstract][Full Text] [Related]  

  • 6. K-ras mutations and RASSF1A promoter methylation in colorectal cancer.
    van Engeland M; Roemen GM; Brink M; Pachen MM; Weijenberg MP; de Bruïne AP; Arends JW; van den Brandt PA; de Goeij AF; Herman JG
    Oncogene; 2002 May; 21(23):3792-5. PubMed ID: 12032847
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Ras effectors NORE1A and RASSF1A are frequently inactivated in pheochromocytoma and abdominal paraganglioma.
    Geli J; Kiss N; Lanner F; Foukakis T; Natalishvili N; Larsson O; Kogner P; Höög A; Clark GJ; Ekström TJ; Bäckdahl M; Farnebo F; Larsson C
    Endocr Relat Cancer; 2007 Mar; 14(1):125-34. PubMed ID: 17395981
    [TBL] [Abstract][Full Text] [Related]  

  • 8. RASSF1A Deficiency Enhances RAS-Driven Lung Tumorigenesis.
    Schmidt ML; Hobbing KR; Donninger H; Clark GJ
    Cancer Res; 2018 May; 78(10):2614-2623. PubMed ID: 29735543
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CpG island promoter hypermethylation of a novel Ras-effector gene RASSF2A is an early event in colon carcinogenesis and correlates inversely with K-ras mutations.
    Hesson LB; Wilson R; Morton D; Adams C; Walker M; Maher ER; Latif F
    Oncogene; 2005 Jun; 24(24):3987-94. PubMed ID: 15806169
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Ras effector NORE1A is suppressed in follicular thyroid carcinomas with a PAX8-PPARgamma fusion.
    Foukakis T; Au AY; Wallin G; Geli J; Forsberg L; Clifton-Bligh R; Robinson BG; Lui WO; Zedenius J; Larsson C
    J Clin Endocrinol Metab; 2006 Mar; 91(3):1143-9. PubMed ID: 16352687
    [TBL] [Abstract][Full Text] [Related]  

  • 11. RASSF1A promoter region CpG island hypermethylation in phaeochromocytomas and neuroblastoma tumours.
    Astuti D; Agathanggelou A; Honorio S; Dallol A; Martinsson T; Kogner P; Cummins C; Neumann HP; Voutilainen R; Dahia P; Eng C; Maher ER; Latif F
    Oncogene; 2001 Nov; 20(51):7573-7. PubMed ID: 11709729
    [TBL] [Abstract][Full Text] [Related]  

  • 12. RASSF3 and NORE1: identification and cloning of two human homologues of the putative tumor suppressor gene RASSF1.
    Tommasi S; Dammann R; Jin SG; Zhang XF; Avruch J; Pfeifer GP
    Oncogene; 2002 Apr; 21(17):2713-20. PubMed ID: 11965544
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epigenetic inactivation of RAS association domain family protein 1 (RASSF1A) in malignant cutaneous melanoma.
    Spugnardi M; Tommasi S; Dammann R; Pfeifer GP; Hoon DS
    Cancer Res; 2003 Apr; 63(7):1639-43. PubMed ID: 12670917
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epigenetic inactivation of the RAS-effector gene RASSF2 in lung cancers.
    Kaira K; Sunaga N; Tomizawa Y; Yanagitani N; Ishizuka T; Saito R; Nakajima T; Mori M
    Int J Oncol; 2007 Jul; 31(1):169-73. PubMed ID: 17549418
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Promoter methylation of RASSF1A and DAPK and mutations of K-ras, p53, and EGFR in lung tumors from smokers and never-smokers.
    Liu Y; Gao W; Siegfried JM; Weissfeld JL; Luketich JD; Keohavong P
    BMC Cancer; 2007 May; 7():74. PubMed ID: 17477876
    [TBL] [Abstract][Full Text] [Related]  

  • 16. RASSF1A promoter methylation and Kras2 mutations in non small cell lung cancer.
    Li J; Zhang Z; Dai Z; Popkie AP; Plass C; Morrison C; Wang Y; You M
    Neoplasia; 2003; 5(4):362-6. PubMed ID: 14511407
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinicopathological significance of epigenetic inactivation of RASSF1A at 3p21.3 in stage I lung adenocarcinoma.
    Tomizawa Y; Kohno T; Kondo H; Otsuka A; Nishioka M; Niki T; Yamada T; Maeshima A; Yoshimura K; Saito R; Minna JD; Yokota J
    Clin Cancer Res; 2002 Jul; 8(7):2362-8. PubMed ID: 12114441
    [TBL] [Abstract][Full Text] [Related]  

  • 18. RASSF1A and NORE1A methylation and BRAFV600E mutations in thyroid tumors.
    Nakamura N; Carney JA; Jin L; Kajita S; Pallares J; Zhang H; Qian X; Sebo TJ; Erickson LA; Lloyd RV
    Lab Invest; 2005 Sep; 85(9):1065-75. PubMed ID: 15980887
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Frequent RASSF1A promoter hypermethylation and K-ras mutations in pancreatic carcinoma.
    Dammann R; Schagdarsurengin U; Liu L; Otto N; Gimm O; Dralle H; Boehm BO; Pfeifer GP; Hoang-Vu C
    Oncogene; 2003 Jun; 22(24):3806-12. PubMed ID: 12802288
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular alterations in spontaneous sputum of cancer-free heavy smokers: results from a large screening program.
    Baryshnikova E; Destro A; Infante MV; Cavuto S; Cariboni U; Alloisio M; Ceresoli GL; Lutman R; Brambilla G; Chiesa G; Ravasi G; Roncalli M
    Clin Cancer Res; 2008 Mar; 14(6):1913-9. PubMed ID: 18347195
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.